The efficiency of subconjunctival bevacizumab in refractory glaucoma - case report.
Anti-vascular endothelial growth factor (anti-VEGF) therapy used as adjunctive to glaucoma filtration surgery may help filtering bleb survival because vascular endothelial growth factor has an important role in the angiogenesis of new vessels and in the fibrogenesis, which lead to scar formation and bleb failure. Bevacizumab is a non-selective monoclonal antibody against all isoforms of VEGF-A. We present the case of an inflammatory glaucoma of a 67-year-old female, with uncontrolled intraocular pressure on maximal tolerable medical treatment, who underwent trabeculectomy and received 1.25 mg/0.05 ml of bevacizumab (Avastin) subconjunctivally at the end of the surgery and an additional injection one month later. Right eye intraocular pressure (IOP) was 26 mm Hg at preoperative visit and after surgery, it decreased and remained normal at each postoperative examination with no additional IOP-lowering medication. A localized avascular bleb with moderate elevation was observed six months postoperatively.
Anatomy Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
V
V
Popescu
Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania.
C
C
Leasu
Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania.
D
D
Stana
Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania.
C
C
Alexandrescu
Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania.
A
A
Dumitrescu
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000494:pharmacology* / Q000627:therapeutic use*; D003228:Conjunctiva / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005901:Glaucoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy
D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
bevacizumab; glaucoma; trabeculectomy; vascular endothelial growth factor